Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36087309/
doi: 10.1002/ejhf.2677. Online ahead of print. 1 Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Kirrberger Str.1, 66421 Homburg/Saar, Germany and Cape Heart Institute, Cape Town, SA. 2 Department of Medicine, University of Mississippi School of Medicine, Department of Medicine (L650), 2500 N. State St, Jackson, MS, 39216, Jackson, MS, USA.
Conclusions: RHR associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events. This article is protected by copyright. All rights reserved.